Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Cogent Biosciences (COGT) EBIAT (2017 - 2026)

Cogent Biosciences' EBIAT history spans 10 years, with the latest figure at -$97.4 million for Q1 2026.

  • Quarterly EBIAT fell 35.3% to -$97.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$354.4 million through Mar 2026, down 68.42% year-over-year, with the annual reading at -$328.9 million for FY2025, 28.55% down from the prior year.
  • EBIAT came in at -$97.4 million for Q1 2026, up from -$102.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$8.5 million in Q1 2023 to a low of -$102.5 million in Q4 2025.
  • The 5-year median for EBIAT is -$58.3 million (2024), against an average of -$52.1 million.
  • Year-over-year, EBIAT soared 74.14% in 2023 and then plummeted 1061.08% in 2025.
  • Cogent Biosciences' EBIAT stood at -$39.6 million in 2022, then skyrocketed by 77.2% to -$9.0 million in 2023, then rose by 2.25% to -$8.8 million in 2024, then tumbled by 1061.08% to -$102.5 million in 2025, then rose by 4.98% to -$97.4 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's EBIAT are -$97.4 million (Q1 2026), -$102.5 million (Q4 2025), and -$80.9 million (Q3 2025).